NabilaNora(Baiti)BennaniMD

PubMed

• 80 citations
  Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy
  Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, John S. Tamaresis, Loretta J. Nastoupil
  Blood. 2020-11-06
• 447 citations
  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
  Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi
  Journal of Clinical Oncology. 2020-05-13
• 22 citations
  Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
  N. Nora Bennani, Betsy R. LaPlant, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards
  American Journal of Hematology. 2017-05-01

Journal Articles

• Genetic Subtyping of Breast Implant-Associated Anaplastic Large Cell Lymphoma  
  Andrew L Feldman, Garry S Brody, Rhett P Ketterling, N Nora Bennani, Mark W Clemens, Ellen D McPhail, Christin A Harless, David S Viswanatha, Rong He, Blood

Abstracts/Posters

• Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis
  Nora N Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Molecular Alterations in Adult Histiocytic Neoplasms
  Nora N Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  N. Nora Bennani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
  Nabila N. Bennani, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018